Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer
Status:
Not yet recruiting
Trial end date:
2029-04-07
Target enrollment:
Participant gender:
Summary
Advanced cervical cancer patients treated with standard of care (SOC) chemoradiation plus
glutaminase inhibition with telaglenastat (CB-839) will have increased progression-free
survival (PFS) compared to historical rates for patients receiving SOC chemoradiation alone.
Phase:
Phase 2
Details
Lead Sponsor:
Washington University School of Medicine
Collaborators:
Calithera Biosciences, Inc National Cancer Institute (NCI)